Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772237 | 1.00 | CYP3A4 (0.44) | CYP3A4ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL24866707 | 0.97 | CHRM2 (0.43) | CYP3A4ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL4301744 | 0.97 | CHRM2 (0.43) | CYP3A4ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL24866499 | 0.97 | CHRM2 (0.43) | CYP3A4ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL4795338 | 0.92 | CHRM2 (0.45) | CYP3A4ALDH1A1CHRM2CHRM1CHRM3 | |
| SCHEMBL4800732 | 0.88 | CHRM2 (0.42) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL6363549 | 0.87 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPTKDM4EPREP | |
| SCHEMBL5798107 | 0.87 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPTKDM4EPREP | |
| SCHEMBL5796713 | 0.87 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPTKDM4EPREP | |
| SCHEMBL1336739 | 0.86 | CHRM2 (0.45) | CYP3A4CHRM2CHRM1CHRM3PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2014648-A1 | PROCESS FOR PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDUCT SALT THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7439036-B2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1536017-B1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL CO (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1536017-A2 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | Sumitomo Chemical Company, Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281331-A1 | METHOD OF PRODUCING POLYCYCLIC PROLINE DERIVATIVE OR ACID ADDITION SALT THEREOF | C9, NPPA, ADH1C | CYP3A4 1867/4885ALDH1A1 372/4885CHRM2 1427/4885 |
| US-20050106690-A1 | Process for producing optically active octahydro-1H-indole-2-carboxylic acid | IDO1, IDO2, APEH | CYP3A4 365/4885ALDH1A1 148/4885CHRM2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.